Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design

DOI10.1016/j.jeconom.2018.12.009zbMath1452.62816OpenAlexW3121524160MaRDI QIDQ2000854

Vahid Montazerhodjat, Andrew W. Lo, Leah Isakov

Publication date: 1 July 2019

Published in: Journal of Econometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/j.jeconom.2018.12.009

zbMATH Keywords

adaptive designFDABayesian decision analysisclinical trial designdrug-approval process

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10)

Related Items (1)

Annals issue in honor of Jerry A. Hausman. Editors' introduction

Cites Work

• Unnamed Item
• Unnamed Item
• Bayesian statistics and the efficiency and ethics of clinical trials
• Choosing sample size for a clinical trial using decision analysis
• Interim Analysis in Clinical Trials: The Role of the Likelihood Principle
• Bayesian Approaches to Randomized Trials
• Clinical Trials

This page was built for publication: Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design